Geode Capital Management LLC Purchases Shares of 255,133 Inhibrx, Inc. (NASDAQ:INBX)

Geode Capital Management LLC bought a new position in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 255,133 shares of the company's stock, valued at approximately $3,930,000. Geode Capital Management LLC owned about 1.76% of Inhibrx at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in INBX. HighTower Advisors LLC bought a new stake in Inhibrx during the 4th quarter worth approximately $12,039,000. Bank of New York Mellon Corp bought a new stake in shares of Inhibrx in the fourth quarter worth $792,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Inhibrx in the fourth quarter worth $503,000. Meridian Wealth Advisors LLC acquired a new stake in Inhibrx in the fourth quarter valued at $385,000. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in Inhibrx during the 4th quarter worth $348,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, JMP Securities reiterated a "market perform" rating on shares of Inhibrx in a research report on Wednesday, January 22nd.

Inhibrx Trading Up 0.1 %

Shares of INBX traded up $0.02 during trading hours on Friday, hitting $12.34. 3,985 shares of the stock were exchanged, compared to its average volume of 193,801. The business has a 50-day moving average of $12.97 and a 200-day moving average of $13.98. Inhibrx, Inc. has a fifty-two week low of $10.80 and a fifty-two week high of $34.75.

Inhibrx (NASDAQ:INBX - Get Free Report) last announced its quarterly earnings data on Monday, March 17th. The company reported ($3.09) EPS for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The firm had revenue of $0.10 million for the quarter. On average, sell-side analysts predict that Inhibrx, Inc. will post 104.88 EPS for the current year.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.